With the increasing incidence of kidney disease, the society pays more and more attention to its treatment. As a common method of kidney disease treatment, hemodialysis has been widely used in the clinical treatment of nephrology. In the stage of dialysis, it is very easy to have all kinds of complications, which will threaten the life of patients. The purpose of this paper is to improve the therapeutic effect by analyzing the common complications of hemodialysis in the department of nephrology. In this paper, the principle and concept of hemodialysis and common diseases in nephrology department were discussed at first. Then, by means of case retrospective analysis, the specific types of common complications in hemodialysis in nephrology department were analyzed, and the specific treatment plans for each complication were proposed. The experimental results showed that: compared with before the treatment of complications, after the treatment of complications, the patient's life risk decreased by about 28%, the treatment effect increased by about 20%, and the recovery rate increased by about 6%. In summary, the timely treatment of complications is related to the therapeutic effect of hemodialysis.

Yuwang Tian. Hemodialysis Therapy and Common Complications in the Department of Nephrology. International Journal of Health and Pharmaceutical Medicine (2021), Vol. 2, Issue 3: 25-35. https://doi.org/10.38007/IJHPM.2021.020303.

[1] Kistler B M, Benner D, Burrowes J D. (2018). “Eating During Hemodialysis Treatment: A Consensus Statement From the International Society of Renal Nutrition and Metabolism”, Journal of Renal Nutrition, 28(1), 4-12. DOI: 10.1053/j.jrn.2017.10.003

[2] Hirose K, Chikamori T, Hida S. (2018). “Application of Pressure-derived Myocardial Fractional Flow Reserve in Chronic Hemodialysis Patients”, Journal of Cardiology, 71(1), 52-58. DOI: 10.1016/j.jjcc.2017.05.007

[3] Desnoyer A, Pospai D, Lê MP. (2016). “Pharmacokinetics, Safety and Efficacy of a Full Dose Sofosbuvir-based Regimen Given Daily in Hemodialysis Patients with Chronic Hepatitis C”, Journal of Hepatology, 65(1), 40-47. DOI: 10.1016/j.jhep.2016.02.044

[4] Truche A S, Darmon M, Sébastien Bailly. (2016). “Continuous Renal Replacement Therapy versus Intermittent Hemodialysis in Intensive Care Patients: Impact on Mortality and Renal Recovery”, Intensive Care Medicine, 42(9), 1-10. DOI: 10.1007/s00134-016-4404-6

[5] Wang X, Tirucherai G, Marbury T C. (2016). “Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Subjects with End-stage Renal Disease on Hemodialysis”, The Journal of Clinical Pharmacology, 56(5), 628-636. DOI: 10.1002/jcph.628

[6] Oishi A, Makita N, Manaka K. (2016). “Successful Glycemic Control with Three Times a Week Degludec Injection by Medical Staff for an Elderly Hemodialysis Patient with Type 2 Diabetes”, Diabetology International, 7(1), 95-99. DOI: 10.1007/s13340-015-0220-4

[7] Block G A, Bushinsky D A, Cheng S. (2017). “Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis with Secondary Hyperparathyroidism a Randomized Clinical Trial”, JAMA The Journal of the American Medical Association, 317(2), 156. DOI: 10.1001/jama.2016.19468

[8] Tariq Shafi, Neil R. Powe, Timothy W. Meyer. (2017). “Trimethylamine N-Oxide and Cardiovascular Events in Hemodialysis Patients”, Journal of the American Society of Nephrology, 28(1), 321. DOI: 10.1681/ASN.2016030374

[9] Vaduganathan M, Bhatt D L. (2016). “Elevated Troponin Levels in Stable Patients Undergoing Hemodialysis: A Red Flag or a Red Herring”, American Journal of Nephrology, 43(3), 170-172. DOI: 10.1159/000445363

[10] Almasri J, Alsawas M, Mainou M. (2016). “Outcomes of Vascular Access for Hemodialysis: A Systematic Review and Meta-analysis”, Journal of Vascular Surgery, 64(1), 236-243. DOI: 10.1016/j.jvs.2016.01.053

[11] Wong J, Sridharan S, Berdeprado J. (2016). “Predicting Residual Kidney Function in Hemodialysis Patients Using Serum β-trace Protein and β2-microglobulin”, Kidney International, 89(5), 1090-1098. DOI: 10.1016/j.kint.2015.12.042

[12] Ko S M, Zhang C, Chen Z. (2016). “Epicardial Adipose Tissue Volume Increase in Hemodialysis Patients Treated with Sevelamer or Calcium-based Phosphate Binders: A Substudy of the Renagel in New Dialysis Trial”, Journal of Nephrology, 29(5), 683-690. DOI: 10.1007/s40620-016-0310-9